查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049676

骨髓惡性腫瘤市場報告：按類型、治療方法、最終用戶和地區分類（2026-2034 年）

Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球骨髓惡性腫瘤市場規模達700億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,339億美元，2026年至2034年的複合年成長率（CAGR）為7.25%。市場成長的主要促進因素包括血液腫瘤發生率的上升、基於基因的標靶治療療法和免疫療法的日益普及，以及專注於血液腫瘤新型療法的生物製藥研發管線的擴展。

骨髓惡性腫瘤市場的發展趨勢：

血液癌症發生率上升

血液癌症發生率的激增以及對新治療方法研發的日益重視是骨髓惡性腫瘤市場成長的主要促進因素。根據 Globocan 2020 的數據，亞洲白血病的發生率估計最高，2020 年確診病例達 230,650 例，其次是歐洲（100,020 例）和北美（67,784 例）。因此，全球白血病的高發生率預計將推動骨髓惡性腫瘤市場的成長。同樣，根據全球癌症觀察站的數據，2020 年北美地區報告了約 67,784 例白血病病例和約 35,318 例多發性骨髓瘤病例。根據白血病和淋巴瘤協會的數據，截至 2021 年，美國估計有 397,501 人患有白血病或處於緩解期。因此，預計血液癌症病例的顯著增加將推動預測期內骨髓惡性腫瘤市場的價值成長。

增加新產品發布、合作夥伴關係和合作研究。

許多公司正在採取各種策略舉措，包括推出新產品、建立夥伴關係、組成聯盟以及進行併購，以擴大市場佔有率。這反過來又對骨髓惡性腫瘤市場的前景產生了積極影響。例如，2020年10月，Astra Zeneca製藥印度公司宣布推出商品名為「Calquence」的acalabrutinib 100毫克膠囊，用於治療多種類型的白血病（慢性淋巴性白血病（CLL）和小淋巴細胞淋巴瘤）。同樣，2024年1月，塔塔紀念醫院研發出印度首個用於治療白血病的口服化療藥物。這項突破性進展有望徹底改變癌症治療，特別是對於急性淋巴性白血病（ALL）等骨髓惡性腫瘤，為傳統片劑提供更精準、更適合兒童使用的替代方案。預計此類創新將在未來幾年內擴大骨髓惡性腫瘤市場的需求。

核准產品數量增加

一系列針對骨髓惡性腫瘤治療藥物的核准，為整個市場帶來了光明的前景。例如，2020年9月，美國食品藥物管理局（FDA）核准了百時美施貴寶公司的Azacitidine（Onureg）300毫克片劑（CC-486），用於成人急性骨髓性白血病患者的後續治療。同樣，2021年3月，賽諾菲公司的salcrisa（isatuximab）獲得FDA核准，可與Carfilzomib和地塞米松聯合治療復發或難治性多發性骨髓瘤患者。因此，2021年2月，TG Therapeutics Inc.的UKONIQ（umbralisib）獲得美國FDA加速批准。 UKONIQ是一種每日一次口服的Delta和酪蛋白激酶1（CK1）ε抑制劑，用於治療復發或難治性邊緣區淋巴瘤（MZL）和復發或難治性濾泡性淋巴瘤（FL）成人患者。血液腫瘤治療核准核准的顯著核准正在提升骨髓惡性腫瘤市場的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球骨髓惡性腫瘤市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 其他

第7章 市場區隔：依療法分類

  • 化療
  • 放射治療
  • 免疫療法
  • 幹細胞移植
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 診斷中心
  • 研究機構
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112026A4133

The global hematologic malignancies market size reached USD 70.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 133.9 Billion by 2034, exhibiting a growth rate (CAGR) of 7.25% during 2026-2034. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.

Hematologic Malignancies Market Trends:

Rising Prevalence of Blood Cancer

Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.

Growing Number of Product Launches, Partnerships, and Collaborations

Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.

Increasing Product Approvals

Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.

Global Hematologic Malignancies Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global hematologic malignancies market report, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on type, therapy, and end user.

Breakup by Type:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others

The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.

Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.

Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.

Breakup by Therapy:

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

As per the hematologic malignancies market overview, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

Breakup by End User:

  • Hospitals
  • Diagnostics Centers
  • Research Centers
  • Others

The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.

Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.

Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the detailed profiles of the following key players:

  • AbbVie Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report:

  • How big is the hematologic malignancies market?
  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2025
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2025
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million USD), 2026-2034
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players